Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517885 | 0.83 | EGLN3 (0.67) | EGLN3EGLN2FTOEGLN1TOP2A | |
| SCHEMBL3524375 | 0.82 | EGLN3 (0.57) | EGLN3EGLN2FTOEGLN1 | |
| SCHEMBL3522552 | 0.82 | EGLN3 (0.46) | EGLN3EGLN2FTOEGLN1 | |
| SCHEMBL3525356 | 0.81 | EGLN3 (0.43) | EGLN3EGLN2FTOEGLN1 | |
| SCHEMBL3523041 | 0.81 | EGLN3 (0.46) | EGLN3EGLN2FTOEGLN1 | |
| SCHEMBL3517879 | 0.80 | EGLN3 (0.48) | EGLN3EGLN2FTOEGLN1TOP2A | |
| SCHEMBL3517314 | 0.79 | EGLN3 (0.48) | EGLN3EGLN2FTOEGLN1 | |
| SCHEMBL3520456 | 0.78 | EGLN3 (0.43) | EGLN3EGLN2FTOEGLN1RAB9A | |
| SCHEMBL3519390 | 0.78 | EGLN3 (0.69) | EGLN3EGLN2FTOEGLN1 | |
| SCHEMBL3518850 | 0.77 | EGLN3 (0.48) | EGLN3EGLN2FTOEGLN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | claimed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN2 3/4885FTO 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.